Our top pick for
MorphoSys AG is a biotechnology business based in the US. MorphoSys shares (MOR) are listed on the NASDAQ and all prices are listed in US Dollars. MorphoSys employs 640 staff and has a market cap (total outstanding shares value) of USD$3.6 billion.
|Latest market close||USD$28.34|
|52-week range||USD$18.21 - USD$37.9609|
|50-day moving average||USD$27.2771|
|200-day moving average||USD$30.083|
|Wall St. target price||USD$36.39|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.2608|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-4.03%|
|1 month (2020-12-16)||-0.39%|
|3 months (2020-10-16)||1.11%|
|6 months (2020-07-16)||-15.38%|
|1 year (2020-01-16)||-15.55%|
|2 years (2019-01-16)||-4.03%|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-13)||N/A|
Valuing MorphoSys stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MorphoSys's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
MorphoSys's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 46x. In other words, MorphoSys shares trade at around 46x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
|Gross profit TTM||USD$59.7 million|
|Return on assets TTM||3.74%|
|Return on equity TTM||12.31%|
|Market capitalisation||USD$3.6 billion|
TTM: trailing 12 months
There are currently 359,305 MorphoSys shares held short by investors – that's known as MorphoSys's "short interest". This figure is 3% up from 348,967 last month.
There are a few different ways that this level of interest in shorting MorphoSys shares can be evaluated.
MorphoSys's "short interest ratio" (SIR) is the quantity of MorphoSys shares currently shorted divided by the average quantity of MorphoSys shares traded daily (recently around 56229.264475743). MorphoSys's SIR currently stands at 6.39. In other words for every 100,000 MorphoSys shares traded daily on the market, roughly 6390 shares are currently held short.
However MorphoSys's short interest can also be evaluated against the total number of MorphoSys shares, or, against the total number of tradable MorphoSys shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case MorphoSys's short interest could be expressed as 0% of the outstanding shares (for every 100,000 MorphoSys shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable MorphoSys shares, roughly 0 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against MorphoSys.
Find out more about how you can short MorphoSys stock.
We're not expecting MorphoSys to pay a dividend over the next 12 months.
Over the last 12 months, MorphoSys's shares have ranged in value from as little as $18.21 up to $37.9609. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MorphoSys's is 1.0527. This would suggest that MorphoSys's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.